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We demonstrate the potential of cloning by homologous recombination as a rapid method to construct DNA molecules
encoding newly developing hemagglutinins (HA) of influenza A virus. The variable parts of the HA genes were cloned into a
basic construct containing the HA gene from an H3N2 strain. The recombinant DNAs thus created encode different variable
domains with neutralising epitopes from four recently circulating influenza A H3 strains. The technology allows rapid
production of DNA constructs for vaccines that can induce antibody and, particularly, cellular immune responses. These new
constructs were also capable of conferring protection to challenge in mice. The technology may hence be a valuable tool for
rapid adaptation of influenza vaccines to changes in the circulating influenza strains. © 2000 Academic Press
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iINTRODUCTION
Influenza is one of the main causes of death among
the elderly in many countries (Dauer and Serfling, 1961;
Eickhoff et al., 1961; Stanley and Jackson, 1966; Barker et
al., 1982). The most cost-effective medical intervention
against influenza is vaccination. Because the antigenic
determinants of the viral envelope proteins hemaggluti-
nin (HA) and neuraminidase (NA) undergo continuous
immuno-selection during viral spread in the population
(antigenic drift) and existing vaccines elicit only short-
time protective immune responses, vaccination must be
repeated annually (Fitch et al., 1997). The mutation rate of
the RNA encoding these proteins is 1.5 3 1025 per
ucleotide per infectious cycle, compared to 10211 per
incorporated nucleotide in the mammalian genome at
cell division (Parvin et al., 1986). Alteration of a few amino
acids in the HA and NA proteins is often sufficient for
immune escape. For these reasons, the market life of a
vaccine is rarely more than one season, and the selec-
tion of a new vaccine involves prediction of the coming
season’s mutations (Parvin et al., 1986).
DNA vaccines offer a novel approach to immunisation.
DNA encoding a specific antigen is transferred to a host
cell, in which the antigen is expressed and presented to
the host’s immune system, hence eliciting an immune
response. The rapid progress in the field started after
Wolff et al. reported direct gene transfer in vivo following
intramuscular (im) injection of naked plasmid DNA in
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244mice (Wolff et al., 1990). In 1993 Robinson et al. reported
humoral responses and protection against viral chal-
lenge following intramuscular inoculation of the hemag-
glutinin gene (Robinson et al., 1993), and Ulmer et al.
observed the induction of cytotoxic T cells and protective
immune responses to influenza A after intramuscular
injection of plasmid DNA encoding the nucleoprotein
(Ulmer et al., 1993).
In the present study, we examined the possibility of
using cloning by homologous recombination to produce
recombinant DNA vaccine vectors and the cellular ex-
pression of recombinant genes hence constructed. The
variable region of the HA1 domain from four predominant
iruses of the recent influenza seasons in Sweden were
uccessfully introduced in the backbone of a genetically
ifferent influenza A H3N2 HA gene. Also, the immuno-
timulatory and protective capacity of these plasmid con-
tructs were tested in mice in this study. The hypothesis
as that our technology would facilitate cloning of the
ntigen determinant region of an emerging influenza HA,
ermit correct expression, and elicit immune responses
o viral challenge.
RESULTS
loning strategy and amino acid substitution analysis
A basic construct encoding the HA gene from the influ-
nza A/Stockholm/6/96(H3N2) virus was prepared with
tandard cloning techniques. The rationale for using this
train was its predominance in Sweden during the previous
nfluenza season. It was also antigenically identical to the
nfluenza A H3 vaccine strain during 1997–98. When a new
irus emerged [the influenza A/Stockholm/7/97(H3N2)], we
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245BUILDING DNA VACCINES USING HOMOLOGOUS RECOMBINATIONinvestigated whether our DNA construct could be easily
modified to represent the antigenic drift. When the cloning
procedure was established, we also investigated the pos-
sibility to clone in the antigen determinant regions from the
preceding season’s viruses, the influenza A/Netherlands/
18/94(H3N2) and A/Umeå/1/95(H3N2) into the vector han-
dle. When a new, drifted strain appeared, the influenza
A/Stockholm/5/99(H3N2) (Swedish Institute for Infectious
Disease Control, Registered Annuals), the antigen determi-
nant region from this very recent strain was also cloned into
the vector handle. The variable region of the basic hemag-
glutinin gene construct was deleted, leaving a linear vector
handle. The variable regions of the HA1 domains from the
A/Netherlands/18/94(H3N2), A/Umeå/1/95(H3N2), A/Stock-
holm/7/97(H3N2), and the A/Stockholm/5/99(H3N2) iso-
lates were cloned into the A/Stockholm/6/96(H3N2) basic
construct by homologous recombination, replacing the pre-
vious variable region (Fig. 1). Homologous recombination
takes place in the bacterial cell (Bubeck et al., 1993) when
overlapping sequences in the PCR fragment (in our study,
;300 bp) recombine with homologous sequences of the
vector handle. The recombination is catalysed by the host’s
recombination system. Recombination was confirmed by
sequencing, and the approximate sites of homologous re-
combination were analysed by comparing amino acids in
the basic construct and the recombinants (Fig. 2).
As an example, one recombinant clone was analysed
in detail. After homologous recombination with the
A/Stockholm/7/97(H3N2) into the A/Stockholm/6/
96(H3N2) vector handle, nine amino acid substitutions
were identified in the variable region that derived from
the A/Stockholm/7/97(H3N2) primary isolate (Fig. 2). The
amino acid substitutions caused a change in net charge
from 21 to 14 in these positions. Also the aspartic acid
at position 133 in the basic construct was replaced by an
asparagine, followed by a glycine and a threonine. This
would add a site for N-linked glycosylation at position
133 (Alberts et al., 1994). Comparisons of the HA1 from
he A/Stockholm/6/96 and the A/Stockholm/7/97 strains
howed that seven of the nine substitutions mapped
ithin or immediately adjacent to the antigen determi-
ant regions A–C and E (described by Wiley et al., 1981).
Expression of recombinant hemagglutinin
Expression of a hemagglutinin was tested by immu-
nofluorescence and its biological activity was tested by
hemadsorbtion in 293 cells transiently expressing the
recombinant influenza HA [A/Stockholm/7/97(H3N2)] in
the pUACMVSMI2 DNA vaccination vector. Figure 3a
shows the immunostaining of transfected cells at 40 h
posttransfection using the H3-specific monoclonal anti-
body MC3A10-18 as compared to untransfected control
cells. In this particular experiment, ;30% of the cells
stained positive for HA. Similarly transfected cells were
incubated with a standard 0.4% suspension of guinea-pig
i
verythrocytes in PBS used for clinical diagnostics of influ-
enza. In this experiment, ;5% of transfected cells
showed adsorption of erythrocytes, whereas the remain-
ing untransfected cells did not adsorb any erythrocytes
(Fig. 3b). Agglutination of red blood cells (hemadsorp-
tion) by influenza infected cells depends on the binding
of HA expressed on the cell surface to its cellular recep-
tor on erythrocytes; sialic acid linked to protein- or lipid-
bound galactose by a2,6 or a2,3 linkages (Weis et al.,
988).
mmunisation and challenge
Mice were vaccinated with killed virions, the HIV rev
ncoding plasmid, the original HA gene [A/Stockholm/6/
6(H3N2)], or HA DNA produced through homologous
ecombination [A/Stockholm/7/97(H3N2)]. The prechal-
enge antibody titres were analysed by ELISA after one
ooster immunisation. Mean group titres ranged be-
ween 110 and 3750 in DNA-immunised mice as com-
ared to 650 in sera from mice immunised with killed
irions (data not shown). Next the mice were challenged
ith the mouse adapted A/PR/8/34(H1N1) influenza
train. Mice immunised with DNA showed an increased
urvival rate and less body weight loss compared to
ice immunised with killed virions or rev-encoding plas-
ids or unvaccinated animals (Fig. 4).
In a similar immunisation study, we evaluated whether
cellular immune response developed after one single
mmunisation with either a recombinant DNA vaccine
A/Stockholm/5/99(H3N2)], killed virions or control DNA
encoding the HIV-1 rev gene). Lymphocytes from all
ice were strongly stimulated by ConA, demonstrating
he viability of the cells. Four of four mice immunised with
he inactivated influenza virus had a strong and specific
-cell response against influenza A/Stockholm/5/
9(H3N2) in the lymphocyte proliferation assay. Four of
ive mice immunised with the recombinant HA gene had
specific T-cell response against the influenza A/Stock-
olm/5/99(H3N2) virus, showing a very high stimulation
ndex even though there was a nonresponder in this
roup. None of the mice immunised with control DNA
howed any indication of a specific T-cell response
gainst influenza A/Stockholm/5/99(H3N2) (Fig. 5). Only
he mice immunised with the killed virions had HA-
pecific antibodies after one immunisation as deter-
ined by ELISA (data not shown).
DISCUSSION
We have demonstrated that rapid cloning by homolo-
ous recombination offers a means to rapidly construct
NA plasmid vectors encoding new strain-specific hem-
gglutinins and that the functional protein is efficiently
xpressed in mammalian cells. This is potentially usefuln constructing DNAs of emerging influenza strains. The
ector handle approach has advantages over traditional
246 LJUNGBERG ET AL.FIG. 1. Cloning strategy for rapid cloning through homologous recombination. A recombinant HA gene was constructed by homologous
recombination. The variable region of the HA gene from a primary isolate was cloned into a vector handle.
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247BUILDING DNA VACCINES USING HOMOLOGOUS RECOMBINATIONcloning, in that no compatible restriction sites are re-
quired in vector or insert and that ligation is not neces-
sary. Additionally, in frame cloning will always be
achieved. This technology could also be used to rapidly
clone variable regions of RNA encoded antigens from
different viral strains to form multivalent vaccines con-
sisting of a mixture of recombinant DNA plasmids. In our
FIG. 2. Comparison of the hemagglutinin amino acid sequences encode
emagglutinin, influenza A/Stockholm/7(H3N2) PCR fragment, and the A/S
he emerging virus, the influenza A/Stockholm/7/97(H3N2) strain, in the ba
rift caused a change in net charge from 21 to 14 and added a site for
FIG. 3. Hemagglutinin expression. Cells from the 293 cell line were
transfected by recombinant DNA and expression was evaluated by
immunofluorescence (a) or by hemadsorption (b). Immunofluorescence
(a): untransfected control (left) and cells transfected by a plasmid
encoding recombinant HA (right). The cells have been incubated with
mouse monoclonal antibodies to influenza HA, followed by incubation
with FITC-labeled anti-mouse IgG. Cells that express HA appear green
under UV illumination. Hemadsorption (b) of guinea pig erythrocytes to
HEK293 cells transfected with influenza HA in the pUACMVSMI2 DNA
vector. Black arrows indicate clumps of guinea pig erythrocytes ad-
sorbed to HA-expressing HEK293 cells, whereas white arrows show
several single erythrocytes distributed over the lawn of untransfected
293 cells. The figure shows a phase contrast image of live cells in
culture, where erythrocytes appear naturally red.study of the immune responses induced upon vaccina-
tion with these plasmids, only antibody production and
specific T-cell proliferation were studied. Cytotoxic T cell
assays were not included because there are no clearly
identified CTL epitopes for mice in the H3 HA amino acid
sequence.
Primary immunisations with killed influenza virions in
humans typically give a strain-specific immunity. It was
previously described that DNA immunisation appears to
give a broad cross-strain protection to heterologous in-
fluenza strains after immunisation with the nucleoprotein
(NP) gene (Fu et al., 1993, 1997; Ulmer et al., 1998) or with
the NP gene together with the HA gene (Robinson et al.,
1999). In a ferret model system, protection against drifted
influenza A/Stockholm/6/96(H3N2) strain, the vector handle, recombinant
m/7/97(H3N2) strain. The recombinant has the neutralising epitopes from
struct backbone. The amino acid substitutions generated by the antigenic
d glycosylation in these positions.
FIG. 4. Challenge data. Vaccinated mice were challenged with the
heterologous influenza A/PR/8/34(H1N1) virus. Survival (a) and body
weight loss (b) were observed 20 days postchallenge. Mice immunisedd by the
tockholwith DNA have the highest survival rate and the highest mean group
body weight after 20 days.
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248 LJUNGBERG ET AL.antigens was observed after immunisation with NP, HA
and M1 encoding plasmids (Donnelly et al.,1997). How-
ver, protection against the drifted antigen seemed to be
ndependent of the HA-encoding plasmid because im-
unisation with only the NP- and M1-encoding plasmids
also gave significantly better protection than protein vac-
cination. There is reason to believe that a DNA vaccine
might have a greater ability to elicit a cellular immune
response than a killed virion vaccine (Robinson, 1997).
The foreign gene is endogenously expressed and the
proteins subsequently processed, thus mimicking anti-
gen processing during viral infection.
The ability of DNA vaccines to elicit a cellular immune
response is also indicated by our lymphocyte prolifera-
tion data where an influenza specific immune response
was primed following a single immunisation with a HA-
encoding DNA vaccine. The lymphocyte proliferation as-
say gives information about priming of an immune re-
sponse, even if antibody production and/or CTL re-
sponses may still be low. Indeed, antibodies were not
detectable in sera after a single immunisation with the
DNA vaccine despite a strong T-cell response in the
lymphocyte proliferation assay.
In this study our objective was to create a HA DNA
vaccine that could be rapidly modified in accordance
with the antigenic drift of the influenza virus. Even though
a DNA vaccine may elicit an immune response with an
enhanced capability to protect against heterologous vi-
ruses by inducing a T helper 1 (Th1) type response, we
FIG. 5. Box plot illustrating the lymphocyte proliferation stimulation
index (SI) 10th, 25th, 50th (median), 75th, and 90th percentiles after
stimulation of lymphocytes from mice immunised with a recombinant
HA gene encoding the variable region from the A/Stockholm/5/
99(H3N2) virus (n 5 5, responders: 4/5) and mice immunised with
control DNA (the HIV-1 rev gene, n 5 5, responders 5 0) with the
nfluenza A/Stockholm/5/99(H3N2) virus. Only the 25th, 50th (median),
nd 75th percentiles are shown in the mice immunised with killed
nfluenza A/Stockholm/5/99(H3N2) (n 5 4, responders:4/4). Respond-
rs are defined as having a SI.3 and a net cpm.1000.believe that highly specific neutralising antibodies to HA
are important for optimal protection. This is relevant if
j
Donly the HA gene is considered for immunisation be-
cause neutralising antibodies are important for prevent-
ing infection, while cytotoxic T lymphocytes may limit the
severity of systemic disease. Our challenge results indi-
cate that DNA immunisation gave a higher degree of
protection against challenge by a heterologous influenza
strain than did protein vaccination even though this re-
mains to be thoroughly investigated, for instance, in a
primate model. This may reflect an important role of
cellular immunity.
Hemagglutinin-specific B- and T-cell responses were
demonstrated, and we have thus obtained an immuno-
genic vaccine that appears to elicit a unique combination
of both specific B cells and broadly reactive T cells. The
immunisation and challenge experiments were under-
taken to compare the protective efficacy of our DNA
vaccine vector versus a homologous killed virus vaccine
in a mouse model system. No information regarding
cross protection between H3 subtypes could be gath-
ered from the present experiments, but it was clear from
the challenge experiments that immunisation with the
full-length H3 gene protected against challenge with the
mouse-adapted A/PR/8/34 (H1N1) strain. H3 subtype
cross-protection, therefore needs to be studied either in
a different, susceptible animal model, such as the ferret
(Donnelly et al.,1997) or, for in vitro studies of T-cell
reactivity, using constructs encoding isolated variable
domains of the H3 gene. Such experiments are in
progress.
MATERIALS AND METHODS
RNA- and virus isolation
MDCK cells were used to culture six influenza strains:
A/Netherlands/18/94(H3N2), a macaque-adapted strain
kindly donated by G. Rimmelzwaan and A. Osterhaus;
A/Umeå/1/95(H3N2), which is A/Johannesburg/33/94-
like; A/Stockholm/6/96(H3N2), which is A/Wuhan/359/95-
like; A/Stockholm/7/97(H3N2), which is A/Sydney/5/97-
like; and A/Stockholm/5/99(H3N2), which is A/Sydney/5/
97-like; and the A/PR/8/34 (H1N1) strain. Total RNA from
infected cells was extracted with standard techniques
according to Chomczynski and Sacchi (1987). The virus-
containing supernatant (107 TCID50/ml) from the pelleted
nfluenza-infected MDCK cells was used for virus isola-
ion and vaccine production. PEG 6000 (10% w/v) was
dded to the supernatant and incubated at 4°C overnight
ollowed by ultracentrifugation at 28,000 rpm at 4°C for
6 h in a sucrose gradient of 30–60%. The gradient was
ractionated in 1-ml fractions, and the virion-containing
ractions were identified by indirect ELISA with the H3-
pecific monoclonal antibody (MC3A10–18, WHO Collab-
rating Center for Virus and Influenza and Research,
yon, France) to HA and a horseradish peroxidase con-ugated anti-mouse IgG antibody (Dako, Copenhagen,
enmark). The virus-containing fractions were pooled
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formaldehyde in PBS for 2 h. The virus-PFA/PBS suspen-
sion was absorbed with aluminum phosphate at 4°C
overnight before inoculation into the mice.
RT–PCR
The viral RNA precipitate was pelleted and resus-
pended in water and used for reverse transcription with
random 14-mer primers. Enzymes and buffers were from
Boehringer Mannheim (Mannheim, Germany).
Two primers were designed using consensus se-
quences from the HA(H3) gene to yield a PCR product of
1048 bp from the HA region of H3 influenza strains. The
sense primer sequence was: 59-CTATCATTGCTTTGAGC-
TAC-39 and the antisense primer sequence was: 59-CT-
TCCCAACCATTTTCTATG-39 (Life Technologies, Ta¨by,
Sweden).
PCR amplification of the HA gene from the reverse
transcription mixture was performed using an annealing
temperature of 52°C and 30 cycles of amplification. En-
zymes, buffers, and PCR machines were from Perkin–
Elmer (Foster City, Ca).
Cloning through homologous recombination
The basic construct was created by cloning the HA
gene from the influenza A/Stockholm/6/96/(H3N2) into
the pUA CMV SMI2 vector (Fig. 1) by standard proce-
dures (Sambrook et al., 1989). The variable domain of the
HA gene in the basic construct was replaced with the HA
gene from the isolates described (Fig. 1). Basic construct
DNA (10 mg) was cleaved with Eco81I (MBI Fermentas,
Vilnius, Lithuania) and XbaI (Boehringer Mannheim), thus
creating a vector handle. The vector handle was isolated
from the 440-bp Eco81I-XbaI fragment by agarose gel
electrophoresis and purified. The linear vector handle
(1–5 mg) and the PCR fragment (1–5 mg) were used for
eat shock transformation (Alberts et al., 1994; Hanahan
et al., 1995) into competent Escherichia coli XL1 blue
{recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F9proAB lacIqZDM15 Tn10 (Tetr)], Stratagene, La Jolla,
Ca}.
Sequence analysis
Recombinants were analysed by sequencing (ABI
Prism Big Dye Terminator Cycle Sequencing Ready Re-
action Kit) on an ABI Prism 310 Genetic Analyzer (Perkin–
Elmer). Two vector-specific sequencing primers were
designed, the promoter-specific sense primer: 59-
GAGGGGCGGCGACTGAATG-39 and the polyA site spe-
cific anti sense primer: 59-TTAGTAGGTGTTGAAACAATA-
AGT-39.
Expression of recombinant hemagglutininCells from the 293 cell line (human embryonic kidney
cells transformed with adenovirus 5 E1A and E1B genes)(Graham and van der Eb, 1973) were transfected using
calcium phosphate-DNA precipitate according to Chen
and Okayama (1987). The cells were cultured in IMDM
(Life Technologies). Medium was changed 24 h after
transfection, and the cells were harvested after 48 h.
Transfected cells were assayed for gene expression
by immunofluorescence staining of HA with an H3-spe-
cific mAb to HA and a secondary FITC-conjugated anti-
mouse IgG antibody (Chemicon AB, Malmo¨, Sweden).
The ability of the transfected cells to cause hemad-
sorption was assayed by addition of red blood cells
(0.4%) from guinea pigs. Hemadsorption could be de-
tected by light microscopy as adherence of erythrocytes
to the surface of transfected cells.
Immune responses and challenge
The plasmid DNA vaccines were produced in E. coli
XL1 blue and purified by QIAGEN Megaprep (QIAGEN,
Hilden, Germany). Fifty micrograms of DNA was given as
a primary immunisation (25 mg in each hind leg) to
C57BL/6 mice. Approximately 10 mg of inactivated virus
protein (5 mg in each hind leg) was used to immunise
57BL/6 mice by intramuscular (im) injection. The anti-
ody titres (specific IgG and IgM) of the immunised mice
ere measured in wells coated with the appropriate
ntigen [A/Stockholm/7/97(H3N2) or A/Stockholm/5/99
H3N2)] in an indirect ELISA. Briefly, the microtiter wells
ere coated with 100 ml antigen dissolved in PBS in a
1/300 dilution overnight at room temperature. The wells
were washed with 0.9% NaCl solution containing 0.05%
Tween 20, and 100 ml serum diluted 1/50 or 1/500 in
ELISA buffer (1.25g BSA, 0.12 ml Tween, and 250ml PBS)
was added. The plates were incubated at 37°C for 2 h
and washed again. HA-specific antibodies were de-
tected with horseradish peroxidase conjugated goat-an-
ti-mouse IgG and IgM antibodies (Dako). After 2 h at
37°C, the plates were washed, and 100 ml OPD substrate
was added. The colour reaction was stopped by addition
of 2.5M H2SO4. The optical density was determined at
540 nm, and antibody titres were defined as the recipro-
cal of the highest dilution giving a net OD-value higher
than two standard deviations above the OD reading of a
negative sample.
For the challenge study, eight mice were given the
basic construct DNA and eight mice received a plasmid
with a recombinant HA gene encoding the variable re-
gion from the influenza A/Stockholm/7/97(H3N2). Four
mice were given the killed virion vaccine, and four mice
were given a control plasmid encoding the HIV-1 rev
gene under the CMV immediate early promoter (same
dose as for HA encoding DNA vaccine). Another eight
mice were not immunised and served as negative con-
trols. Six weeks after primary immunisation, an intramus-
cular booster dose was administered (same dose as
above). Another 6–8 weeks later the mice were inocu-
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250 LJUNGBERG ET AL.lated by intranasal instillation (25 ml/nostril) according to
Robinson et al. (1997) (with the difference being that the
mice were not anaesthetised) of saline containing a
100-fold dilution of egg-cultured mouse-adapted influ-
enza A/PR/8/34 virus stock (kindly provided by H. L.
Robinson and R. G. Webster). This dose was titrated to
be the LD50 in inoculated C57BL/6 mice.
Lymphocyte proliferation
On Day 23 postimmunisation, spleen cells were taken
from a total of 14 mice immunised once with inactivated
influenza A/Stockholm/5/99(H3N2) (n 5 4, one mouse was
killed by its siblings), DNA vaccine encoding the variable
region of the same virus (n 5 5) or with the DNA vaccine
vector backbone, which served as an unimmunised control
(n 5 5). The spleens were fragmented and lymphocytes
solated by sedimentation. The lymphocytes were washed
nce in phosphate buffered saline (PBS, Unimedic, Matfors,
weden) and then dissolved in RPMI 1640 (Life Technolo-
ies) with 10% inactivated foetal calf serum (FCS, Life Tech-
ologies), 50 U/ml penicillin, and 50 mg/ml streptomycin
nd counted in a CX320 cell coulter. The cells were washed
nd diluted to 2.0 3 106 cells/ml. Cells were aliquoted in a
6-well plate (2.0 3 105/well) with RPMI 1640 and 10% FCS
and with 5 mg/ml Con A (Boehringer Mannheim, Mann-
heim, Germany) as a positive control or influenza A/Stock-
holm/5/99(H3N2) in dilutions 1:20 and 1:40. The plates were
incubated at 37°C for 5 days. After 5 days, 50 ml tritium-
labeled thymidine (1mCi) was added to each well, and the
plates were incubated at 37°C overnight. The cells were
harvested onto nitro-cellulose filters (Wallac, Stockholm,
Sweden) and dried overnight at 58°C. The filters were then
sealed inside a plastic pocket and wet with 4.5 ml Scint
fluid. The level of stimulation was measured as the amount
of incorporated [3H]thymidine. A net count per minute (net
cpm; the cpm of the cells stimulated by the antigen minus
the cpm of cells with medium) exceeding 1000 and a stim-
ulation index (the cpm of the cells stimulated by the antigen
divided by cpm of non stimulated cells) .3 were consid-
ered to be a specific stimulation response.
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